
### [NCIT:C40392](http://purl.obolibrary.org/obo/NCIT_C40392)
**Label:** Myoepithelial Tumor

**Subclasses:** [NCIT:C5978](http://purl.obolibrary.org/obo/NCIT_C5978) (Benign Salivary Gland Myoepithelioma), [NCIT:C6899](http://purl.obolibrary.org/obo/NCIT_C6899) (Breast Adenomyoepithelioma), [NCIT:C5143](http://purl.obolibrary.org/obo/NCIT_C5143) (Malignant Breast Adenomyoepithelioma), [NCIT:C5144](http://purl.obolibrary.org/obo/NCIT_C5144) (Benign Breast Adenomyoepithelioma), [NCIT:C7596](http://purl.obolibrary.org/obo/NCIT_C7596) (Malignant Myoepithelioma), [NCIT:C7442](http://purl.obolibrary.org/obo/NCIT_C7442) (Benign Myoepithelioma), [NCIT:C6581](http://purl.obolibrary.org/obo/NCIT_C6581) (Parachordoma), [NCIT:C40388](http://purl.obolibrary.org/obo/NCIT_C40388) (Periductal Breast Myoepitheliosis), [NCIT:C40389](http://purl.obolibrary.org/obo/NCIT_C40389) (Breast Myoepithelial Tumor), [NCIT:C40395](http://purl.obolibrary.org/obo/NCIT_C40395) (Malignant Breast Myoepithelioma), [NCIT:C121787](http://purl.obolibrary.org/obo/NCIT_C121787) (Malignant Mixed Tumor, Not Otherwise Specified), [NCIT:C121786](http://purl.obolibrary.org/obo/NCIT_C121786) (Mixed Tumor, Not Otherwise Specified), [NCIT:C40385](http://purl.obolibrary.org/obo/NCIT_C40385) (Breast Myoepitheliosis), [NCIT:C40393](http://purl.obolibrary.org/obo/NCIT_C40393) (Salivary Gland Myoepithelial Tumor), [NCIT:C35700](http://purl.obolibrary.org/obo/NCIT_C35700) (Salivary Gland Myoepithelial Carcinoma), 

**Class expressions from DL-Learner:**

- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([NCIT:C36807](http://purl.obolibrary.org/obo/NCIT_C36807) (Dysplastic Epithelial Cell))) 75.00%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([NCIT:C36780](http://purl.obolibrary.org/obo/NCIT_C36780) (Malignant Myoepithelial Cell))) 75.00%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([NCIT:C36779](http://purl.obolibrary.org/obo/NCIT_C36779) (Malignant Epithelial Cell))) 75.00%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([NCIT:C12917](http://purl.obolibrary.org/obo/NCIT_C12917) (Malignant Cell))) 75.00%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) 60.36%
- [NCIT:C36769](http://purl.obolibrary.org/obo/NCIT_C36769) (Abnormal Myoepithelial Cell) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([CHEBI:22868](http://purl.obolibrary.org/obo/CHEBI_22868) (bile salt))) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([CHEBI:22563](http://purl.obolibrary.org/obo/CHEBI_22563) (anion))) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([CHEBI:17089](http://purl.obolibrary.org/obo/CHEBI_17089) (glycoprotein))) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([CHEBI:16990](http://purl.obolibrary.org/obo/CHEBI_16990) (bilirubin))) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([CHEBI:16541](http://purl.obolibrary.org/obo/CHEBI_16541) (protein polypeptide chain))) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([CHEBI:16336](http://purl.obolibrary.org/obo/CHEBI_16336) (hyaluronic acid))) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([CHEBI:15440](http://purl.obolibrary.org/obo/CHEBI_15440) (squalene))) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not ([CHEBI:10545](http://purl.obolibrary.org/obo/CHEBI_10545) (electron))) 60.36%
- [NCIT:C36770](http://purl.obolibrary.org/obo/NCIT_C36770) (Neoplastic Myoepithelial Cell) and (not (CARO:0010000)) 60.36%


